Search
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalApproved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.
Fluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor AntagonistsTrolamine salicylate
go.drugbank.com/drugs/DB11079ApprovedTriethanolamine neutralizes the acidity of the salicylic acid. … Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains.
Products: Ultracin T, Dr Joe lab ARTHRITIS EXTRA STRENGTHThiohexam
go.drugbank.com/drugs/DB14200ApprovedSensitivity to Thiohexam may be identified with a clinical patch test.
Ethionamide
go.drugbank.com/drugs/DB00609ApprovedInvestigationalWithdrawnIt also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Acebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Categories: Adrenergic beta-1 Receptor AntagonistsBetazole
go.drugbank.com/drugs/DB00272ApprovedA histamine H2 agonist used clinically to test gastric secretory function.
Clonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigational[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists